Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
NCT05603104 · Dr. Inge Winter · PHASE3 · terminated · last registry update 2026-11-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.” | – | Registry record, Dr. Inge Winter |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (terminated): Negovsky Reanimatology Research Institute, Sevoflurane + Propofol (NCT05259631)
- 2026-09-09Also stopped (terminated): Apsen Farmaceutica S.A., Fixed Dose Combination + Etodolac (NCT03127592)
- 2026-08-24Phase 3 first posted: Bukwang Pharmaceutical, Lurasidone + Placebo (NCT07781293)
- 2026-05-22Also stopped (terminated): OrthoCarolina Research Institute, Inc., a drug against HTR2A (NCT02202369)
- 2026-05-13Results posted on the registry: University Hospital, Clermont-Ferrand, Dexmedetomidine (NCT03317067)
- 2026-02-25Also stopped (terminated): Ohio State University, Clozapine + Antipsychotics,Other (non-Clozapine) (NCT05741502)
- 2026-02-11Phase 3 first posted: University of Michigan, Cyclobenzaprine (NCT07404397)
- 2025-12-22Phase 3 first posted: University of California, San Francisco, Pharmacologic Pain Management (NCT07296770)
- 2025-12-03Results posted on the registry: ACADIA Pharmaceuticals Inc., Pimavanserin (NCT05555615)
- 2025-12-03Also stopped (terminated): ACADIA Pharmaceuticals Inc., Pimavanserin (NCT05555615)
- 2025-11-24Phase 3 first posted: Mercy Bon Secours Saint Vincent Medical Center, Olanzapine 10 milligram + Haloperidol (NCT07246187)
- 2025-11-12Phase 3 first posted: NeuroRx, Inc., NRX-101 + Oral Placebo (NCT07227103)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision